Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Shell PLC — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Shell PLC trades at $103.96 (market cap $294.95B). The key difference: Shell PLC is far larger — about 301.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Shell PLC pays a 3.02% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Shell PLC for 91 Days on average.
| MRVI | SHEL | |
|---|---|---|
Market Cap | $977.37M | $294.95B |
Volume | 2,742,564 | 6,021,309 |
Sector | Health | Energy |
52-Week High | $9.00 | $103.58 |
52-Week Low | $2.83 | $70.31 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $1.08B | $336.65B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Shell (SHEL) trades at $102.99, up 1.38% on the day, near its 52-week high. The stock shows strong technical momentum with bullish moving averages, though oscillators indicate overbought conditions. Fundamentally, the company delivered earnings beats in Q1 and Q2 2026, with a forward P/E of 11.39 suggesting reasonable valuation. Recent news highlights strategic LNG expansion, including the Phase 2 approval for LNG Canada, positioning Shell for long-term growth in global gas markets.
The outlook for Shell remains positive, supported by robust cash flows, strategic investments in LNG, and a favorable analyst consensus with 62% buy ratings. Key risks include exposure to volatile oil prices and execution challenges in major projects. The stock offers value through dividends and growth potential, but investors should monitor energy market dynamics and project timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
